American Society of Hematology. (2017).
Nilotinib Label Update to Include Treatment Discontinuation Recommendations for CML With Sustained Molecular Responses.
Retrieved from https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2017/nilotinib-label-upd-incl-treatment-discontinuation-recommendations-cml-sustained-molecular-resp.
American Society of Hematology.
"Nilotinib Label Update to Include Treatment Discontinuation Recommendations for CML With Sustained Molecular Responses." Hematology.org.
https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2017/nilotinib-label-upd-incl-treatment-discontinuation-recommendations-cml-sustained-molecular-resp
(label-accessed April 26, 2024).
"American Society of Hematology."
Nilotinib Label Update to Include Treatment Discontinuation Recommendations for CML With Sustained Molecular Responses, 26 Apr. 2024 ,
https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2017/nilotinib-label-upd-incl-treatment-discontinuation-recommendations-cml-sustained-molecular-resp.
